Skip to content

Dr Sushant Mittal
Director Oncology
Balaji Action Cancer Hospital
DM(Medical Oncology), AIIMS, Delhi
Tata Memorial Cancer, Mumbai

Dr. Sushant Mittal – Leading Medical Oncologist in Delhi NCR

Expert in Breast, Lung, Prostate, Colon Cancers | Specialist in Immunotherapy & Targeted Therapy

Looking for the best oncologist in Delhi NCR? I’m Dr. Sushant Mittal, a highly trained and compassionate medical oncologist with extensive experience in providing advanced, personalized cancer treatment. I specialize in diagnosing and managing all major types of cancers, including lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, and blood cancers.

I received my oncology training from the prestigious Tata Memorial Hospital, one of India’s top cancer institutes, and follow global, evidence-based protocols to ensure my patients receive the most effective treatment possible.

Work Experience: 17+ years

  • Senior Residency (Internal Medicine) at Sri Ganga Ram Hospital, Delhi: July 2008 to May 2009
  • Senior Residency (Medical Oncology) at IRCH, AIIMS, Delhi: June 2009 to July 2010
  • DM Medical Oncology at Tata Memorial Centre, Mumbai: August 2010 to July 2013
  • Associate consultant at Fortis Memorial Research Centre, Gurgaon: August 2013 to September 2014
  • Consultant in Artemis Health Institute, Gurgaon: September 2014 to December 2016
  • Director, at Action Cancer Hospital, Delhi: January 2017 to till date

Education & Training

  • Free Paper presentation at API chapter, Pune held on 1-2nd April 2007
  • “DISH with Hypokalemic Periodic Paralysis” paper presentation at API chapter, Delhi, October 2008.
  • Case presentation (Phyllodes tumour) at Young ICON conference in Delhi on 12th March 2011
  • Presentation on Translocation associated Renal Cell Carcinoma, at GOKARM, June 2011
  • “Incidence, outcome and risk factor for Engraftment fever in post autologus transplant in lymphoma patients” – Poster presentation in Indian Society of Hematology and Transfusion Medicine, 15th November 2011.
  • Poster presentation on Engraftment Syndrome at European Lymphoma and Leukemia meeting, Feb 2012
  • Attended the ACORD workshop, Brisbane, Australia in September 2012: Workshop on Cancer Clinical Research Methods to develop a research protocol titled: A pharmacokinetic study to evaluate and validate the use of limited sampling in predicting MMF levels in allogeneic transplant patients.
  • “Retrospective analysis of primary CNS lymphoma patients at Tata Memorial Center.” Oral presentation in Asian Socitey of Neuro-oncology on 22nd March 2013
  • ASCO June 2013 – poster presentation on updated analysis of Engraftment Syndrome
  • Utility of PET scan in preclinical diagnosis of Bleomycin induced lung toxicity in Hodgkin Lymphoma patients (DM thesis)) (accepted for Poster Presentation at ESMO 2013, Amsterdam to be held in September2013
  • Oral presentation on Choice of oral TKI in EGFR mutated lung cancer makes a difffrence at UAE cancer congress October 2015.

Research & Publication

  • Department of Medical Oncology
    Tata Memorial Centre, Mumbai
    Utility of PET scan in preclinical diagnosis of Bleomycin induced lung toxicity in Hodgkin Lymphoma patients (DM thesis))(accepted for Poster Presentation at ESMO 2013, Amsterdam to be held in September2013
    Role : Chief Investigator
  • Department of Medical Oncology
    Tata Memorial Centre, Mumbai
    Retrospective analysis of primary CNS lymphoma patients at Tata Memorial Center.
    Role : Chief Investigator
  • Incidence of gastro intestinal manifestations in HIV positive patients (MD thesis)
  • TZ-01-002: A Randomized, Double-Blind, Multicentre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2- Positive Metastatic Breast Cancer” as Co PI
  • SB3-G31-BC: “A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting”. as Co PI
  • A multicentre, randomized, open label, two period, two treatment, two way crossover, comparative bioavailability study at Steady state comparing Capecitabine Extended release Capsule 500mg (Intas Pharmaceuticals Ltd, India) to the reference listed drug Xeloda (Capecitabine 500mg ; Roche Pharmaceuticals) in patients of Breast Cancer or Colorectal cancer under fed condition as Co PI
  • A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of First-line recurrent or Metastatic Squamous Cell Head & neck cancer patients. as PI
  • A multicenter, open label, balanced, randomized, two treatment, three period, three sequence, reference replicate crossover, single dose, oral bioequivalence study of Capecitabine film coated tablets 500mg of Shilpa Medicare Limited, India & Xeloda film coated tablets 500mg (Capecitabine) marketed by Roche Registration limited, 6 Falcon way, Shire park, Welwyn garden city, AL71 TW United Kingdome following single oral dose of 2000mg (4x500mg) in adult human cancer patients under fed conditions as Co PI
  • A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of Metastatic Lung cancer as PI
  • A Randomized, Open-Label, Multi-Center Phase III Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) as PI
  • A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center,
  • International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) as PI
  • An open label, observational, multicentric, prospective, single arm, drug utilization surveillance study to evaluate safety and efficacy of Abiraterone acetate in chemonaive patients with metastatic prostate cancer as Co PI
  • An active surveillance to monitor the real world safety in Indian patients prescribed nintedanib for the treatment of locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

Areas of Expertise – Best Cancer Specialist Near You

If you’re searching for the best cancer specialist, here’s how I can help:

  • Breast Cancer Specialist in Delhi NCR
    If you’re looking for the best breast cancer doctor, I deliver compassionate, stage-specific care with a focus on long-term wellness and recovery.
  • Lung Cancer Specialist
    As a top lung cancer doctor in Delhi, I offer cutting-edge treatments like targeted therapy, immunotherapy, and personalized chemotherapy. Many patients looking for a “lung cancer specialist near me” choose my clinic for accurate diagnosis and modern treatment options.
  • Prostate Cancer Specialist
    Recognized as a trusted prostate cancer oncologist in Delhi NCR, I provide customized treatment plans, collaborating closely with surgeons and urologists for best outcomes in both early and advanced-stage prostate cancers.
  • Colon Cancer Specialist
    As a leading colon cancer doctor in Delhi NCR, I provide advanced treatment options including targeted therapy, chemotherapy, and personalized care plans. Patients searching for a “colon cancer specialist near me” rely on my expertise for early diagnosis, effective treatment, and ongoing support through every stage of the disease.
  • Immunotherapy Specialist
    As a trusted immunotherapy doctor in Delhi NCR, I offer cutting-edge cancer treatments that harness the body’s immune system to fight cancer more effectively. Patients searching for an “immunotherapy specialist near me” choose my clinic for access to the latest advancements in immune checkpoint inhibitors, CAR T-cell therapy, and personalized cancer care.
  • Targeted Therapy Specialist
    As a leading targeted therapy doctor in Delhi NCR, I provide advanced, precision-based cancer treatments that focus on specific genetic mutations and cancer cell markers. Patients searching for a “targeted therapy specialist near me” trust my expertise in delivering personalized therapies for cancers like lung, breast, colon, and prostate—maximizing effectiveness while minimizing side effects.

Memberships

  • Member of the American Society of Clinical Oncology (ASCO)
  • Member of the European Society of Medical Oncology (ESMO)
  • Member of DMC & MCI
  • Member of ISMPO & ICON